AN2 Therapeutics
ANTX
37 hedge funds and large institutions have $20.1M invested in AN2 Therapeutics in 2024 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 12 increasing their positions, 7 reducing their positions, and 6 closing their positions.
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
71% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 7
39% more capital invested
Capital invested by funds: $14.5M → $20.1M (+$5.59M)
19% more funds holding
Funds holding: 31 → 37 (+6)
3.34% more ownership
Funds ownership: 45.29% → 48.62% (+3.3%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Almitas Capital
Santa Monica,
California
|
+$1.59M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$512K |
| 3 |
Two Sigma Advisers
New York
|
+$494K |
| 4 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
+$479K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$448K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$2.14M |
| 2 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$1.66M |
| 3 |
AI
Acuitas Investments
Seattle,
Washington
|
-$477K |
| 4 |
Millennium Management
New York
|
-$229K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$84.9K |
ANTX Hedge Fund Activity: Q4 2024 in Review
37 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in AN2 Therapeutics (ANTX) for Q4 2024, worth a combined $20.1M — up 39% from $14.5M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ANTX positions and 6 closed out — a net gain of 6 holders — while 12 added to existing stakes and 7 trimmed.
The largest buyer was Almitas Capital, opening a new position worth an estimated $1.59M. The largest seller was RA Capital Management, exiting entirely with an estimated $2.14M sold.
- 37 institutional investors held AN2 Therapeutics (ANTX) as of Q4 2024, up from 31 in Q3 2024.
- Funds reported $20.1M of AN2 Therapeutics stock for Q4 2024, up 39% quarter-over-quarter.
- 12 funds opened new AN2 Therapeutics positions in Q4 2024 and 6 closed out, a net change of +6 holders.
- The largest AN2 Therapeutics buyer in Q4 2024 was Almitas Capital, an estimated $1.59M added.
- The largest AN2 Therapeutics seller in Q4 2024 was RA Capital Management, an estimated $2.14M sold.
Based on aggregated 13F filings for Q4 2024.